

**B.1. Allergy/Immunology**

In addition to the considerations discussed in the introductory language of Table B of the appendix of this final rule, the Allergy/Immunology specialty set takes additional criteria into consideration, which includes, but is not limited to: whether the measure reflects current clinical guidelines and the coding of the measure includes relevant clinician types. We may reassess the appropriateness of individual measures, on a case-by-case basis, to ensure appropriate inclusion in the specialty set. Measure tables in this set include previously finalized measures that we are maintaining within the set, measures that were proposed to be added, and measures that were proposed for removal, as applicable.

**B.1. Allergy/Immunology**

PREVIOUSLY FINALIZED MEASURES IN THE ALLERGY/IMMUNOLOGY SET								
Indicator	NQ F # / eCQM NQ F #	Quality #	CMS eCQM ID	Collection Type	Measure Type	National Quality Strategy Domain	Measure Title And Description	Measure Steward
*	0041 / 0041 e	110	CMS147v10	Medicare Part B Claims Measure Specifications, eCQM Specifications, CMS Web Interface Measure Specifications, MIPS CQMs Specifications	Process	Community /Population Health	<b>Preventive Care and Screening: Influenza Immunization:</b> Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization.	National Committee for Quality Assurance
	N/A / N/A	111	CMS127v9	Medicare Part B Claims Measure Specifications, eCQM Specifications, MIPS CQMs Specifications	Process	Community /Population Health	<b>Pneumococcal Vaccination Status for Older Adults:</b> Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine.	National Committee for Quality Assurance
* ! (Patient Safety)	0419 / 0419 e	130	CMS68v10	Medicare Part B Claims Measure Specifications, eCQM Specifications, MIPS CQMs Specifications	Process	Patient Safety	<b>Documentation of Current Medications in the Medical Record:</b> Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter.	Centers for Medicare & Medicaid Services
* §	0028 / 0028 e	226	CMS138v9	Medicare Part B Claims Measure Specifications, eCQM Specifications, CMS Web Interface Measure Specifications, MIPS CQMs Specifications	Process	Community / Population Health	<b>Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention:</b> Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 12 months AND who received tobacco cessation intervention if identified as a tobacco user.  Three rates are reported: a. Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 12 months b. Percentage of patients aged 18 years and older who were identified as a tobacco user who received tobacco cessation intervention c. Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 12 months AND who received tobacco cessation intervention if identified as a tobacco user.	National Committee for Quality Assurance
* ! (Patient Safety)	0022 / N/A	238	CMS156v9	eCQM Specifications, MIPS CQMs Specifications	Process	Patient Safety	<b>Use of High-Risk Medications in Older Adults:</b> Percentage of patients 65 years of age and older who were ordered at least two of the same high-risk medications.	National Committee for Quality Assurance
*	N/A / N/A	317	CMS22v9	Medicare Part B Claims Measure Specifications, eCQM Specifications, MIPS CQMs Specifications	Process	Community / Population Health	<b>Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented:</b> Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is pre-hypertensive or hypertensive.	Centers for Medicare & Medicaid Services

B.1. Allergy/Immunology

PREVIOUSLY FINALIZED MEASURES IN THE ALLERGY/IMMUNOLOGY SET								
Indicator	NQF # / eCQM / M / NQF #	Quality #	CMS eCQM ID	Collection Type	Measure Type	National Quality Strategy Domain	Measure Title And Description	Measure Steward
§ ! (Outcome)	2082 / N/A	338	N/A	MIPS CQMs Specifications	Outcome	Effective Clinical Care	<b>HIV Viral Load Suppression:</b> The percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.	Health Resources and Services Administration
§ ! (Efficiency)	2079 / N/A	340	N/A	MIPS CQMs Specifications	Process	Efficiency and Cost Reduction	<b>HIV Medical Visit Frequency:</b> Percentage of patients, regardless of age with a diagnosis of HIV who had at least one medical visit in each 6 month period of the 24 month measurement period, with a minimum of 60 days between medical visits.	Health Resources and Services Administration
* ! (Care Coordination)	N/A / N/A	374	CMS50v9	eCQM Specifications, MIPS CQMs Specifications	Process	Communication and Care Coordination	<b>Closing the Referral Loop: Receipt of Specialist Report:</b> Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.	Centers for Medicare & Medicaid Services
	2803 / N/A	402	N/A	MIPS CQMs Specifications	Process	Community / Population Health	<b>Tobacco Use and Help with Quitting Among Adolescents:</b> The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user.	National Committee for Quality Assurance

## B.1. Allergy/Immunology

MEASURES FINALIZED FOR ADDITION TO THE ALLERGY/IMMUNOLOGY SET									
Indicator	NQF # / eCQM NQF #	Quality #	CMS eCQM ID	Collection Type	Measure Type	National Quality Strategy Domain	Measure Title And Description	Measure Steward	Rationale for Inclusion
* ! (Appropriate Use)	N/A / N/A	331	N/A	MIPS CQMs Specifications	Process	Efficiency and Cost Reduction	<b>Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse):</b> Percentage of patients, aged 18 years and older, with a diagnosis of acute viral sinusitis who were prescribed an antibiotic within 10 days after onset of symptoms.	American Academy of Otolaryngology – Head and Neck Surgery Foundation	This measure was proposed for inclusion into the Allergy/Immunology specialty set based on previous stakeholder feedback during previous comment period. Allergists/immunologists treat and frequently manage sinusitis. As such, we agreed with the stakeholder and proposed to add to the Allergy/Immunology specialty set.
* ! (Appropriate Use)	N/A / N/A	332	N/A	MIPS CQMs Specifications	Process	Efficiency and Cost Reduction	<b>Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use):</b> Percentage of patients aged 18 years and older with a diagnosis of acute bacterial sinusitis that were prescribed amoxicillin, with or without clavulanate, as a first line antibiotic at the time of diagnosis.	American Academy of Otolaryngology – Head and Neck Surgery Foundation	This measure was proposed for inclusion into the Allergy/Immunology specialty set based on previous stakeholder feedback during previous comment period. Allergists/immunologists treat and frequently manage sinusitis. As such, we agreed with the stakeholder and proposed to add to the Allergy/Immunology specialty set.
! (Outcome)	N/A / N/A	398	N/A	MIPS CQMs Specifications	Outcome	Effective Clinical Care	<b>Optimal Asthma Control:</b> Composite measure of the percentage of pediatric and adult patients whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools and not at risk for exacerbation.	Minnesota Community Measurement	This measure was proposed for inclusion into the Allergy/Immunology specialty set based on previous stakeholder feedback during previous comment period. Allergists/immunologists treat and frequently manage asthma. As such, we agreed with the stakeholder and proposed to add to the Allergy/Immunology specialty set.

B.1. Allergy/Immunology

MEASURES FINALIZED FOR ADDITION TO THE ALLERGY/IMMUNOLOGY SET									
Indicator	NQF # / eCQM NQF #	Quality #	CMS eCQM ID	Collection Type	Measure Type	National Quality Strategy Domain	Measure Title And Description	Measure Steward	Rationale for Inclusion
* ! (Efficiency)	N/A / N/A	444	N/A	MIPS CQMs Specifications	Process	Efficiency and Cost Reduction	<b>Medication Management for People with Asthma:</b> The percentage of patients 5-64 years of age during the performance period who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period.	National Committee for Quality Assurance	This measure was proposed for inclusion into the Allergy/Immunology specialty set based on previous stakeholder feedback during previous comment period. Allergists/Immunologists treat and frequently manage asthma. As such, we agreed with the stakeholder and proposed to add to the Allergy/Immunology specialty set.
<p><b>Comment:</b> One commenter thanked CMS for the addition of measures Q331, Q332, Q398, and Q444 to the Allergy/Immunology set that it had requested in prior years comments.</p> <p><b>Response:</b> We thank the commenter for supporting the addition of the four measures to this specialty set.</p> <p>After consideration of public comments, we are finalizing the measures for addition to the <i>Allergy/Immunology Specialty Measure Set</i> as proposed for the 2021 MIPS performance period/2023 MIPS payment year and future years.</p>									